Literature DB >> 9924961

Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia.

N Berhe1, S G Gundersen, F Abebe, H Birrie, G Medhin, T Gemetchu.   

Abstract

A total of 611 Schistosoma mansoni infected primary school children from three schools in north-east Ethiopia were treated with praziquantel at 40 mg/kg body weight in a single dose. Pre-treatment, 40.4% had no presenting symptoms and 30-40% had nausea, abdominal cramps and/or bloody-mucoid diarrhoea. None of the pre-treatment symptoms was related to nutritional status, intensity of S. mansoni egg excretion, or to the presence of other concomitant intestinal parasitic infections. During the first 4-6 h post-treatment observation period, 90 (14.7%) children self-presented with severe gastro-intestinal symptoms. Children who self-presented with severe symptoms had a higher mean age and mean S. mansoni egg excretion compared with children who did not self-present. The following day a total of 529 (86.6%) children, including all who self-presented during the first 4-6 h post-treatment, reported for clinical check-up and were subjected to a structured questionnaire interview on symptoms they had experienced over the time lapse following treatment. Among these, 91.5% reported one or more treatment related symptoms which were at times severe. Abdominal cramps (86.9%), diarrhoea with blood and/or mucus (49.5%), dizziness (31.2%) and vomiting (24.9%) were the most common treatment related symptoms. Skin rash with oedema were observed in four cases. Among treatment related symptoms, the combination of abdominal cramps with vomiting, bloody diarrhoea, vomiting alone and general weakness were significantly higher among the malnourished. A proportion of these symptoms increased with increasing categories of S. mansoni egg excretion before and after adjusting for nutritional status and concurrent intestinal parasitic infections. Overall, the cure rate of praziquantel, among 541 children who had stool examination 5 weeks after treatment was 83.2% and this rate decreased with increasing pre-treatment egg counts. In conclusion, most of the treatment related symptoms were mild. However, some of the objective symptoms were at times severe and may reduce drug compliance in primary health care based population chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9924961     DOI: 10.1016/s0001-706x(98)00084-9

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  17 in total

Review 1.  Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.

Authors:  Nuno Vale; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Fátima Gärtner; José M Correia da Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel.

Authors:  Claus M Reimert; Colin M Fitzsimmons; Sarah Joseph; Joseph K Mwatha; Frances M Jones; Gachuhi Kimani; Karl F Hoffmann; Mark Booth; Narcis B Kabatereine; David W Dunne; Birgitte J Vennervald
Journal:  Clin Vaccine Immunol       Date:  2006-05

3.  Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia.

Authors:  Berhanu Erko; Abraham Degarege; Konjit Tadesse; Asnake Mathiwos; Mengistu Legesse
Journal:  Asian Pac J Trop Biomed       Date:  2012-03

4.  Efficacy of Praziquantel against Schistosoma haematobium in Dulshatalo village, western Ethiopia.

Authors:  Asaye Mekonnen; Mengistu Legesse; Mulugeta Belay; Konjit Tadesse; Workineh Torben; Zelalem Teklemariam; Berhanu Erko
Journal:  BMC Res Notes       Date:  2013-09-30

Review 5.  Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials.

Authors:  Julien Zwang; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

6.  Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.

Authors:  Mitiku Bajiro; Daniel Dana; Mio Ayana; Daniel Emana; Zeleke Mekonnen; Belay Zawdie; Asfaw Garbi; Ashenafi Kure; Ahmed Zeynudin
Journal:  Parasit Vectors       Date:  2016-10-24       Impact factor: 3.876

7.  Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children.

Authors:  Mahamadou S Sissoko; Abdoulaye Dabo; Hamidou Traoré; Mouctar Diallo; Boubacar Traoré; Drissa Konaté; Boubacar Niaré; Moussa Diakité; Bourama Kamaté; Abdrahamane Traoré; Aboudramane Bathily; Amadou Tapily; Ousmane B Touré; Sarah Cauwenbergh; Herwig F Jansen; Ogobara K Doumbo
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

8.  Changes in IgE- and antigen-dependent histamine-release in peripheral blood of Schistosoma mansoni-infected Ugandan fishermen after treatment with praziquantel.

Authors:  Mohamed Z Satti; Pierre Cahen; Per S Skov; Sarah Joseph; Frances M Jones; Colin Fitzsimmons; Karl F Hoffmann; Claus Reimert; H Curtis Kariuki; Francis Kazibwe; Joseph K Mwatha; Gachuhi Kimani; Birgitte J Vennervald; John H Ouma; Narcis B Kabatereine; David W Dunne
Journal:  BMC Immunol       Date:  2004-04-21       Impact factor: 3.615

9.  A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya.

Authors:  Sammy M Njenga; Paul M Ng'ang'a; Mariam T Mwanje; Fatuma S Bendera; Moses J Bockarie
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

10.  The cytotoxicity study of praziquantel enantiomers.

Authors:  Qian Sun; Ruifeng Mao; Dongling Wang; Changyan Hu; Yang Zheng; Dequn Sun
Journal:  Drug Des Devel Ther       Date:  2016-06-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.